2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1693

To What Extend Do Auto-Antibodies Help to Identify High-Risk Patients in Systemic Sclerosis?
Abstract Number: 1645

Tobacco Exposure and Relationship with Severe Damage in Systemic Lupus Erythematosus Patients
Abstract Number: 447

Tocilizumab Had Acceptable Retention Rate in Both Randomized Controlled Trials and Observational Studies: Systematic Review of Rheumatoid Arthritis
Abstract Number: 2751

Tocilizumab in the Treatment of Severe and/or Refractory Behcet’s Disease：a Single-Centre Experience in China
Abstract Number: 2458

Tocilizumab Inhibits Progression of Erosive Joint Damage in Early Rheumatoid Arthritis More Effectively Than Step-up Methotrexate Therapy
Abstract Number: 623

Tofacitinib Improves Composite Endpoint Measures of Disease in Patients with Psoriatic Arthritis
Abstract Number: 1421

Tofacitinib Monotherapy Improves Arterial Stiffness in Conventional Dmards Active Rheumatoid Arthritis Patients. a Cohort Study
Abstract Number: 507

Tofacitinib Monotherapy Improves Left Ventricular Mass and Cardiac Output in Patients with Rheumatoid Arthritis
Abstract Number: 880

Tofacitinib Treatment in Patients with Psoriatic Arthritis and Rates of Radiologic Progression According to Baseline CRP Levels: Results from a Phase 3 Clinical Study
Abstract Number: 1906

Tofacitinib with and without Methotrexate Versus Adalimumab with Methotrexate for the Treatment of Rheumatoid Arthritis: Patient-Reported Outcomes from a Phase 3b/4 Randomized Trial
Abstract Number: 522

Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Efficacy in Open-Label, Long-Term Extension Studies over 9 Years
Abstract Number: 1741

Tolerance and Efficiency of Anti-Programmed Death 1 Antibodies in Patients with Cancer and Preexisting Autoimmune or Inflammatory Diseases
Abstract Number: 1686

Topical Nitroglycerine (NTG) Vs Matching Vehicle in Secondary Raynaud Phenomenon (RP) – a Double-Blind Crossover Study of Subjective and Physiologic Responses to Controlled Cold Challenge
Abstract Number: 311

Total Ankle Arthroplasty for Rheumatoid Arthritis Cases in This Biologics Era: Mid to Long-Term Follow-up
Abstract Number: 1492

Total Body Water Correlates with Ocular Sicca Symptoms in Primary SjöGren’s Syndrome

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].